

Dan Atar

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7905728/dan-atar-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

244
papers

38,407
citations

54
h-index

195
g-index

291
ext. papers

44,716
ext. citations

5.6
avg, IF

6.16
L-index

#	Paper	IF	Citations
244	The Role of ECG in the Diagnosis and Risk Stratification of Acute Coronary Syndromes: an Old but Indispensable Tool.. <i>Current Cardiology Reports</i> , 2022 , 24, 109	4.2	1
243	Do We Really Need Aspirin Loading for STEMI?. <i>Cardiovascular Drugs and Therapy</i> , 2022 , 1	3.9	0
242	Performance of the Novel Observation Group Criteria of the European Society of Cardiology (ESC) 0/1-Hour Algorithm in a Low-Risk Population.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024927	6.2	0
241	No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab.. <i>PLoS ONE</i> , 2022 , 17, e0266615	3.7	0
240	Diagnostic Accuracy and Usability of the ECG247 Smart Heart Sensor Compared to Conventional Holter Technology. <i>Journal of Healthcare Engineering</i> , 2021 , 2021, 5230947	3.7	2
239	Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction : An International Collaborative Meta-analysis. <i>Annals of Internal Medicine</i> , 2021 ,	8	5
238	MVnet: automated time-resolved tracking of the mitral valve plane in CMR long-axis cine images with residual neural networks: a multi-center, multi-vendor study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021 , 23, 137	6.9	1
237	Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data. <i>BMJ, The</i> , 2021 , 375, e066450	5.9	0
236	Is RBBB the new LBBB? Are we going to repeat the same mistakes?. <i>Journal of Electrocardiology</i> , 2021 , 65, 34-36	1.4	0
235	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021 , 23, 1612-1676	3.9	99
234	The Times They Are A-Changin': Antithrombotic strategies in patients with acute coronary syndrome undergoing coronary stenting who have concomitant atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2021 , 88, 21-22	3.9	0
233	Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. <i>Heart Failure Reviews</i> , 2021 , 26, 1421-1435	5	13
232	GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. <i>Future Cardiology</i> , 2021 , 17, 19-38	1.3	6
231	Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design. <i>American Heart Journal</i> , 2021 , 231, 96-104	4.9	20
230	The perils of data sharing, meta-analyses, and estimating cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e55-e57	6.4	
229	Efficacy of Long-Term Oral Beta-Blocker Therapy in Patients Who Underwent Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Preserved Left Ventricular Ejection Fraction: A Systematic Review and Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2021 , 77, 87-93	3.1	0
228	Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry. <i>Annals of Medicine</i> , 2021 , 53, 485-494	1.5	

227	Use of Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention across the Stroke Spectrum: Progress and Prospects. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 716-730	7	1
226	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <i>Atherosclerosis</i> , 2021 , 319, 51-61	3.1	12
225	Comparison of a single high-sensitivity cardiac troponin T measurement with the HEART score for rapid rule-out of acute myocardial infarction in a primary care emergency setting: a cohort study. <i>BMJ Open</i> , 2021 , 11, e046024	3	1
224	Modulating the Intensity of Oral Anticoagulation Therapy with Direct Oral Anticoagulants: Feasible or Not?. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 1	4	1
223	The debated issue of direct oral anticoagulants correct dosing: When even the reviewer is confused. <i>European Journal of Internal Medicine</i> , 2021 , 90, 125-126	3.9	
222	Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. <i>Clinical Research in Cardiology</i> , 2021 , 1	6.1	5
221	Prevalence of genetically verified familial hypercholesterolemia among young (. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 339-345	4.9	2
220	Worst lead ST deviation and resolution of ST elevation at one hour for prediction of myocardial salvage, infarct size, and microvascular obstruction in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. <i>Annals of Noninvasive Electrocardiology</i> , 2020 , 25, e12784	1.5	2
219	Biomarkers Associated with Atrial Fibrillation in Patients with Ischemic Stroke: A Pilot Study from the NOR-FIB Study. <i>Cerebrovascular Diseases Extra</i> , 2020 , 10, 11-20	2.1	4
218	Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. <i>Trials</i> , 2020 , 21, 415	2.8	5
217	Self-Care Monitoring of Heart Failure Symptoms and Lung Impedance at Home Following Hospital Discharge: Longitudinal Study. <i>Journal of Medical Internet Research</i> , 2020 , 22, e15445	7.6	8
216	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	2
215	The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events. <i>Europace</i> , 2020 , 22, 195-204	3.9	13
214	Pre-hospital One-Hour Troponin in a Low-Prevalence Population of Acute Coronary Syndrome: OUT-ACS study. <i>Open Heart</i> , 2020 , 7,	3	3
213	Inferior ST-Elevation Myocardial Infarction Presenting When Urgent Primary Percutaneous Coronary Intervention Is Unavailable: Should We Adhere to Current Guidelines?. <i>Cardiovascular Drugs and Therapy</i> , 2020 , 34, 865-870	3.9	3
212	ESC Core Curriculum for the Cardiologist. <i>European Heart Journal</i> , 2020 , 41, 3605-3692	9.5	12
211	The cancer patient and cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 2290-2309	12.3	22
210	Does Ivabradine Decrease Cardiovascular Deaths in Heart Failure Patients?. <i>American Journal of Medicine</i> , 2020 , 133, 347-351	2.4	1

209	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 86-93	6.4	15
208	The myth of 'stable' coronary artery disease. <i>Nature Reviews Cardiology</i> , 2020 , 17, 9-21	14.8	39
207	Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials. <i>Heart Failure Reviews</i> , 2020 , 25, 161-171	5	4
206	Angiotensin receptor neprilysin inhibition for the treatment of hypertension: the neglected child in cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 122-123	6.4	1
205	Gender differences in association between uric acid and all-cause mortality in patients with chronic heart failure. <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 4	2.3	10
204	Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure - A multicenter propensity score matched analysis. <i>International Journal of Cardiology</i> , 2019 , 289, 83-90	3.2	6
203	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 171-180	6.4	26
202	Atrial fibrillation in cryptogenic stroke and transient ischaemic attack - The Nordic Atrial Fibrillation and Stroke (NOR-FIB) Study: Rationale and design. <i>European Stroke Journal</i> , 2019 , 4, 172-180	5.6	6
201	Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>American Heart Journal</i> , 2019 , 215, 83-90	4.9	0
200	B-type natriuretic peptide trumps other prognostic markers in patients assessed for coronary disease. <i>BMC Medicine</i> , 2019 , 17, 72	11.4	6
199	Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe. <i>Heart</i> , 2019 , 105, 1252-1259	5.1	9
198	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. <i>Journal of the American Heart Association</i> , 2019 , 8, e010510	6	24
197	On-label reduced doses of non-vitamin K anticoagulants prove safe and efficient; yet how to ensure the correct dose for the right patient?. <i>European Heart Journal</i> , 2019 , 40, 1501-1503	9.5	4
196	Fourth universal definition of myocardial infarction (2018).. <i>European Heart Journal</i> , 2019 , 40, 237-269	9.5	851
195	Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 589-597	3.9	19
194	Heat Stress Impacts on Cardiac Mortality in Nepali Migrant Workers in Qatar. <i>Cardiology</i> , 2019 , 143, 37-48.6		27
193	Gender but not diabetes, hypertension or smoking affects infarct evolution in ST-elevation myocardial infarction patients - data from the CHILL-MI, MITOCARE and SOCCER trials. <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 161	2.3	3
192	Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. <i>American Journal of Medicine</i> , 2019 , 132, 1431-1440.e7	2.4	5

191	Health Care Professionals' Perceptions of Home Telemonitoring in Heart Failure Care: Cross-Sectional Survey. <i>Journal of Medical Internet Research</i> , 2019 , 21, e10362	7.6	17
190	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. <i>Circulation</i> , 2019 , 139, 2292-2300	16.7	47
189	Ivabradine for heart failure: regulatory differences in Europe and United States. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 119-121	6.4	
188	All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. <i>American Journal of Therapeutics</i> , 2019 , 26, e671-e678	1	2
187	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1596-1604	12.3	35
186	Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 210-215	6.4	3
185	Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019 , 24, 215-224	2.6	4
184	BETablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study. <i>American Heart Journal</i> , 2019 , 208, 37-46	4.9	10
183	The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. <i>Heart Failure Reviews</i> , 2018 , 23, 303-323	5	27
182	Correlation of anteroseptal ST elevation with myocardial infarction territories through cardiovascular magnetic resonance imaging. <i>Journal of Electrocardiology</i> , 2018 , 51, 563-568	1.4	4
181	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. <i>European Heart Journal</i> , 2018 , 39, 464-473	9.5	25
180	European Society of Cardiology: Cardiovascular Disease Statistics 2017. <i>European Heart Journal</i> , 2018 , 39, 508-579	9.5	395
179	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018 , 20, 395-407	3.9	66
178	Longitudinal left ventricular function is globally depressed within a week of STEMI. <i>Clinical Physiology and Functional Imaging</i> , 2018 , 38, 1029	2.4	6
177	Correlation of ST changes in leads V4-V6 to area of ischemia by CMR in inferior STEMI. <i>Scandinavian Cardiovascular Journal</i> , 2018 , 52, 189-195	2	1
176	Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants. <i>Scandinavian Cardiovascular Journal</i> , 2018 , 52, 156-162	2	6
175	Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018 , 4, 82-92	6.4	7
174	Appropriateness of anteroseptal myocardial infarction nomenclature evaluated by late gadolinium enhancement cardiovascular magnetic resonance imaging. <i>Journal of Electrocardiology</i> , 2018 , 51, 218-223	1.4	1

173	Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>International Journal of Cardiology</i> , 2018 , 272, 260-266	3.2	13
172	The significance of ST-elevation in aVL in anterolateral myocardial infarction: An assessment by cardiac magnetic resonance imaging. <i>Annals of Noninvasive Electrocardiology</i> , 2018 , 23, e12580	1.5	7
171	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018 , 11, e004962	7.6	70
170	In Current Clinical Practice, after Percutaneous Coronary Intervention for Acute Myocardial Infarction, Are β -Blockers Prescribed for Heart Failure or as Secondary Prevention? A Pilot Study. <i>Cardiology</i> , 2018 , 140, 152-154	1.6	3
169	Response to the editor. <i>Heart Failure Reviews</i> , 2018 , 23, 819	5	
168	Electrocardiographic scores of severity and acuteness of myocardial ischemia predict myocardial salvage in patients with anterior ST-segment elevation myocardial infarction. <i>Journal of Electrocardiology</i> , 2018 , 51, 195-202	1.4	3
167	Cardiac Magnetic Resonance Evaluation of the Extent of Myocardial Injury in Patients with Inferior ST Elevation Myocardial Infarction and Concomitant ST Depression in Leads V1-V3: Analysis from the MITOCARE Study. <i>Cardiology</i> , 2018 , 140, 178-185	1.6	6
166	Author's response to: letter to the editor. <i>Heart Failure Reviews</i> , 2018 , 23, 819	5	
165	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018 , 70, 828-835	1.6	10
164	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017 , 103, 307-314	5.1	163
163	Spirolactone Treatment and Effect on Survival in Chronic Heart Failure Patients with Reduced Renal Function: A Propensity-Matched Study. <i>CardioRenal Medicine</i> , 2017 , 7, 128-136	2.8	4
162	Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , 2017 , 106, 711-721	6.1	24
161	Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials. <i>International Journal of Cardiology</i> , 2017 , 244, 59-66	3.2	16
160	Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 147-150	6.4	14
159	Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. <i>International Journal of Cardiology</i> , 2017 , 238, 97-104	3.2	3
158	2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017 , 70, 50	0.7	124
157	Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. <i>Stroke</i> , 2017 , 48, 3266-3273	6.7	13
156	Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative. <i>International Journal of Cardiology</i> , 2017 , 249, 274-281	3.2	1

155	Neurohormonal Blockade in Heart Failure. <i>Cardiac Failure Review</i> , 2017 , 3, 19-24	4.2	27
154	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2017 , 38, 852-859	9.5	50
153	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017 , 38, 860-868	9.5	75
152	Myocardium at risk assessed by electrocardiographic scores and cardiovascular magnetic resonance - a MITOCARE substudy. <i>Journal of Electrocardiology</i> , 2017 , 50, 725-731	1.4	4
151	Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention. <i>Data in Brief</i> , 2017 , 14, 197-205	1.2	10
150	Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins. <i>Cardiology</i> , 2017 , 138, 122-132	1.6	4
149	Time-resolved tracking of the atrioventricular plane displacement in Cardiovascular Magnetic Resonance (CMR) images. <i>BMC Medical Imaging</i> , 2017 , 17, 19	2.9	26
148	Patient engagement. <i>European Heart Journal</i> , 2017 , 38, 3114-3115	9.5	9
147	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017 , 38, 1710-1716	9.5	38
146	ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. <i>European Heart Journal</i> , 2017 , 38, 143-153	9.5	337
145	Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. <i>European Heart Journal</i> , 2016 , 37, 747-54	9.5	46
144	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016 , 37, 2893-2962	9.5	4465
143	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016 , 18, 1609-1678	3.9	1293
142	Extent of Myocardium at Risk for Left Anterior Descending Artery, Right Coronary Artery, and Left Circumflex Artery Occlusion Depicted by Contrast-Enhanced Steady State Free Precession and T2-Weighted Short Tau Inversion Recovery Magnetic Resonance Imaging. <i>Circulation: Cardiovascular Imaging</i> , 2016 , 9, 27-34	3.9	14
141	'Ten Commandments' of 2016 ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2016 , 37, 2853	9.5	27
140	A new automatic algorithm for quantification of myocardial infarction imaged by late gadolinium enhancement cardiovascular magnetic resonance: experimental validation and comparison to expert delineations in multi-center, multi-vendor patient data. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016 , 18, 27	6.9	47
139	Automatic segmentation of myocardium at risk from contrast enhanced SSFP CMR: validation against expert readers and SPECT. <i>BMC Medical Imaging</i> , 2016 , 16, 19	2.9	8
138	Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016 , 2, 52-57	4.6	3

137	Assessment of Right Ventricular Afterload in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016 , 13, 176-85	2	3
136	Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint. <i>Journal of the American Heart Association</i> , 2016 , 5, e002708	6	27
135	Multi-vendor, multicentre comparison of contrast-enhanced SSFP and T2-STIR CMR for determining myocardium at risk in ST-elevation myocardial infarction. <i>European Heart Journal Cardiovascular Imaging</i> , 2016 , 17, 744-53	4.1	40
134	Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. <i>European Journal of Heart Failure</i> , 2016 , 18, 482-9	12.3	49
133	Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. <i>Heart</i> , 2015 , 101, 1475-84	5.1	10
132	Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study. <i>Circulation: Heart Failure</i> , 2015 , 8, 887-96	7.6	16
131	Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis. <i>International Journal of Cardiology</i> , 2015 , 186, 104-5	3.2	22
130	Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. <i>Circulation: Heart Failure</i> , 2015 , 8, 71-8	7.6	183
129	ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 31-6	6.4	19
128	Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. <i>European Heart Journal</i> , 2015 , 36, 112-9	9.5	129
127	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 86-94	6.4	44
126	Expanding the Evidence Base: Comparing Randomized Controlled Trials and Observational Studies of Statins. <i>American Journal of Therapeutics</i> , 2015 , 22, e141-50	1	7
125	Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2015 , 17, 1144-51	12.3	63
124	Increased LV apical untwist during preload reduction in healthy humans: an echocardiographic speckle tracking study during lower body negative pressure. <i>Physiological Reports</i> , 2015 , 3, e12330	2.6	6
123	The National Cardiac Societies of the European Society of Cardiology. <i>European Heart Journal</i> , 2015 , 36, 1278	9.5	
122	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. <i>European Heart Journal</i> , 2015 , 36, 3268-75	9.5	30
121	The Effects of Climate Change on Cardiac Health. <i>Cardiology</i> , 2015 , 131, 209-17	1.6	37
120	Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2015 , 169, 257-265.e1	4.9	28

119	Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. <i>Clinical Chemistry</i> , 2015 , 61, 368-78	5.5	29
118	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2015 , 17, 194-206	3.9	30
117	High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>Circulation</i> , 2014 , 129, 625-34	16.7	86
116	Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. <i>European Heart Journal</i> , 2014 , 35, 2516-23	9.5	65
115	High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 52-61	15.1	114
114	A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2014 , 16, 308-19	3.9	224
113	Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014 , 35, 224-32	9.5	118
112	Obstructive sleep apnea: no independent association to troponins. <i>Sleep and Breathing</i> , 2014 , 18, 351-8	3.1	6
111	Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. <i>JACC: Cardiovascular Imaging</i> , 2014 , 7, 930-9	8.4	195
110	Comorbidities and polypharmacy. <i>Heart Failure Clinics</i> , 2014 , 10, 367-72	3.3	17
109	Myeloid-related protein-8/14 and C-reactive protein in individuals evaluated for obstructive sleep apnea. <i>Sleep Medicine</i> , 2014 , 15, 762-8	4.6	3
108	Fatal sepsis and systemic inflammatory response syndrome after off-label prasugrel: a case report. <i>American Journal of Therapeutics</i> , 2014 , 21, e229-33	1	5
107	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014 , 35, 1864-72	9.5	237
106	Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade. <i>Fundamental and Clinical Pharmacology</i> , 2014 , 28, 353-63	3.1	9
105	The association between meteorological events and acute heart failure: new insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014 , 177, 819-24	3.2	9
104	Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2281-93	15.1	313
103	Effects of FX06 in vitro on platelet, coagulation, and fibrinolytic biomarkers in volunteers and patients with documented coronary artery disease. <i>American Journal of Therapeutics</i> , 2014 , 21, 91-8	1	1
102	Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and Valsartan Impact in Diabetics pilot trial. <i>American Journal of Therapeutics</i> , 2014 , 21, 482-90	1	

101	Current role of neprilysin inhibitors in hypertension and heart failure. <i>Pharmacology & Therapeutics</i> , 2014 , 144, 41-9	13.9	49
100	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2013 , 15, 456-64	12.3	32
99	Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. <i>International Journal of Cardiology</i> , 2013 , 168, 2510-7	3.2	14
98	Pharmacological conversion of recent-onset atrial fibrillation: a systematic review. <i>Scandinavian Cardiovascular Journal</i> , 2013 , 47, 2-10	2	24
97	Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?. <i>European Heart Journal</i> , 2013 , 34, 1630-5	9.5	36
96	Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. <i>Circulation: Heart Failure</i> , 2013 , 6, 594-605	7.6	98
95	Cost effectiveness of drug-eluting stents as compared with bare metal stents in patients with coronary artery disease. <i>American Journal of Therapeutics</i> , 2013 , 20, 596-601	1	5
94	Regional LV deformation in healthy individuals during isovolumetric contraction and ejection phases assessed by 2D speckle tracking echocardiography. <i>Clinical Physiology and Functional Imaging</i> , 2012 , 32, 372-9	2.4	4
93	The L-arginine/asymmetric dimethylarginine ratio is improved by anti-tumor necrosis factor- β therapy in inflammatory arthropathies. Associations with aortic stiffness. <i>Atherosclerosis</i> , 2012 , 225, 160-5	3.1	20
92	Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. <i>European Journal of Heart Failure</i> , 2012 , 14, 1257-64	12.3	82
91	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. <i>Europace</i> , 2012 , 14, 1385-413	3.9	1019
90	Third universal definition of myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1581-98	15.1	2143
89	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. <i>European Heart Journal</i> , 2012 , 33, 2719-47	9.5	2638
88	Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 412-4	7	23
87	Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. <i>Thrombosis and Haemostasis</i> , 2012 , 107, 338-45	7	24
86	Effect of 1-year anti-TNF- β therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. <i>American Journal of Hypertension</i> , 2012 , 25, 644-50	2.3	108
85	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012 , 33, 2569-619	9.5	3978
84	Increased heart rate variability during nondirective meditation. <i>European Journal of Preventive Cardiology</i> , 2012 , 19, 773-80	3.9	30

83 Conclusion. *Advances in Cardiology*, **2012**, 47, 165

82	Changes in diagnosing non-ST-segment elevation myocardial infarction after the introduction of a new high-sensitivity cardiac troponin T assay: a single-centre experience. <i>Clinical Laboratory</i> , 2012 , 58, 1029-36	2	3
81	Troponin I degradation in serum of patients with acute ischemic stroke. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2011 , 71, 74-80	2	3
80	Dronedarone in high-risk permanent atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 2268-76	59.2	438
79	Apixaban with antiplatelet therapy after acute coronary syndrome. <i>New England Journal of Medicine</i> , 2011 , 365, 699-708	59.2	765
78	Apixaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 981-92	59.2	5856
77	Gender differences among Norwegian patients with heart failure. <i>International Journal of Cardiology</i> , 2011 , 146, 354-8	3.2	18
76	Fatty Acid binding protein 4 is associated with carotid atherosclerosis and outcome in patients with acute ischemic stroke. <i>PLoS ONE</i> , 2011 , 6, e28785	3.7	40
75	Corrigendum to: Guidelines for the management of atrial fibrillation [European Heart Journal (2010) 31, 2369-2429 and EP-Europace (2010) 12, 1360-1420]. <i>European Heart Journal</i> , 2011 , 32, 1172-1172	9.5	3
74	Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies. <i>Fundamental and Clinical Pharmacology</i> , 2011 , 25, 511-7	3.1	16
73	Reduced preload elicits increased LV twist in healthy humans: an echocardiographic speckle-tracking study during lower body negative pressure. <i>Clinical Physiology and Functional Imaging</i> , 2011 , 31, 382-9	2.4	14
72	Activated leukocyte cell adhesion molecule and prognosis in acute ischemic stroke. <i>Stroke</i> , 2011 , 42, 2453-8	6.7	19
71	Relation of cardiac troponin I and microvascular obstruction following ST-elevation myocardial infarction. <i>Acute Cardiac Care</i> , 2011 , 13, 48-51		4
70	Early prediction of increased arterial stiffness in patients with chronic inflammation: a 15-year followup study of 108 patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2011 , 38, 606-12	4.1	33
69	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011 , 32, 1854-64	9.5	273
68	Incremental value of a combination of cardiac troponin T, N-terminal pro-brain natriuretic peptide and C-reactive protein for prediction of mortality in end-stage renal disease. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011 , 45, 151-8		11
67	Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 812-7	2.4	83
66	Amyotrophic lateral sclerosis (ALS), a novel rare cause of elevated plasma troponin T levels. <i>Clinical Laboratory</i> , 2011 , 57, 615-8	2	8

65	'Treat to target': moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 629-30	2.4	46
64	Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. <i>Hypertension</i> , 2010 , 55, 333-8	8.5	122
63	Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. <i>European Heart Journal</i> , 2010 , 31, 227-35	9.5	56
62	NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1946-50	2.4	28
61	Corrigendum to ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 [Eur Heart J 2008;29:2388-442 and Eur J Heart Fail 2008;10:933-89]. <i>European Journal of Heart Failure</i> , 2010 , 12, 416-416	12.3	1
60	A window into your heart: taking cardiac troponin to the next level. <i>Biomarkers in Medicine</i> , 2010 , 4, 889-94	2.4	2
59	The PLATO trial: do you believe in magic?. <i>European Heart Journal</i> , 2010 , 31, 764-7	9.5	17
58	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2010 , 31, 2369-429	9.5	3452
57	COPD predicts mortality in HF: the Norwegian Heart Failure Registry. <i>Journal of Cardiac Failure</i> , 2010 , 16, 225-9	3.3	56
56	Maximizing scientific knowledge from randomized clinical trials. <i>American Heart Journal</i> , 2010 , 159, 937-43	4.3	10
55	Androgenic anabolic steroid abuse and the cardiovascular system. <i>Handbook of Experimental Pharmacology</i> , 2010 , 411-57	3.2	69
54	Influence of ST-segment recovery on infarct size and ejection fraction in patients with ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2010 , 105, 1223-8	3	11
53	Optimal time-point of ST-segment assessment for risk-stratification following primary percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2010 , 105, 1648-9; author reply 1649-50	3	
52	Impact of time to therapy and presence of collaterals on the efficacy of FX06 in acute ST elevation myocardial infarction: a substudy of the F.I.R.E., the Efficacy of FX06 in the prevention of myocardial reperfusion injury trial. <i>EuroIntervention</i> , 2010 , 5, 946-952	3.1	8
51	Hotline sessions of the 30th European Congress of Cardiology. <i>European Heart Journal</i> , 2009 , 30, 1151	9.5	
50	Usefulness of natriuretic peptide testing for long-term risk assessment following acute ischemic stroke. <i>American Journal of Cardiology</i> , 2009 , 104, 287-91	3	24
49	Relation of cardiac troponin I measurements at 24 and 48 hours to magnetic resonance-determined infarct size in patients with ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2009 , 104, 1472-7	3	47
48	Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 27, 48-56	5.1	55

47	Antiplatelet 'resistance' and 'non-responders': what do these terms really mean?. <i>Fundamental and Clinical Pharmacology</i> , 2009 , 23, 11-8	3.1	6
46	Interpreting clinical trials: the 'beautiful' case. <i>Fundamental and Clinical Pharmacology</i> , 2009 , 23, 261-2	3.1	1
45	Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance". <i>American Heart Journal</i> , 2009 , 158, 925-32	4.9	59
44	Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 720-9	15.1	123
43	Clinical review: impact of statin substitution policies on patient outcomes. <i>Annals of Medicine</i> , 2009 , 41, 242-56	1.5	21
42	Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. <i>Fundamental and Clinical Pharmacology</i> , 2008 , 22, 315-21	3.1	48
41	Comparison of four different cardiac troponin assays in patients with end-stage renal disease on chronic haemodialysis. <i>Acute Cardiac Care</i> , 2008 , 10, 173-80		6
40	Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?. <i>Cerebrovascular Diseases</i> , 2008 , 26, 563-4	3.2	
39	Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2008 , 25, 207-13	5.1	21
38	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>European Heart Journal</i> , 2008 , 29, 2544-54	9.5	2298
37	Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 314-8	7	3
36	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and the invited expert). <i>European Heart Journal</i> , 2007 , 28, 2475-514	9.5	1029
35	Frequency and significance of troponin T elevation in acute ischemic stroke. <i>American Journal of Cardiology</i> , 2007 , 99, 108-12	3	128
34	Assessment of bleeding events in clinical trials--proposal of a new classification. <i>American Journal of Cardiology</i> , 2007 , 99, 288-90	3	59
33	Mechanism of troponin elevations in patients with acute ischemic stroke. <i>American Journal of Cardiology</i> , 2007 , 99, 867-70	3	67
32	The relation between electrocardiographic ST-T changes and NT-proBNP in patients with acute ischemic stroke. <i>Scandinavian Cardiovascular Journal</i> , 2007 , 41, 294-8	2	5
31	Rheumatic mitral valve stenosis mimicking advanced lung cancer. <i>Heart and Vessels</i> , 2007 , 22, 345-8	2.1	1
30	Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study. <i>Neuropsychopharmacology</i> , 2007 , 32, 2369-74	8.7	17

29	Rationale and design of the 'F.I.R.E.' study. A multicenter, double-blind, randomized, placebo-controlled study to measure the effect of FX06 (a fibrin-derived peptide Bbeta(15-42)) on ischemia-reperfusion injury in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. <i>Cardiology</i> , 2007 , 108, 117-23	1.6	14
28	Asymptomatic myocardial infarction prior to ischemic stroke?. <i>Cerebrovascular Diseases</i> , 2007 , 24, 318	3.2	0
27	Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIFY Thrombosis risk ASsessment (VERITAS) study. <i>Thrombosis Research</i> , 2007 , 119, 277-84	8.2	174
26	Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?. <i>Thrombosis Research</i> , 2007 , 119, 175-81	8.2	6
25	Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease. <i>American Heart Journal</i> , 2007 , 153, 371-7	4.9	9
24	Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness. <i>Cerebrovascular Diseases</i> , 2006 , 21, 98-105	3.2	15
23	Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy. <i>Circulation Research</i> , 2006 , 99, 1141-7	15.7	38
22	Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans. <i>Journal of Clinical Psychopharmacology</i> , 2006 , 26, 172-7	1.7	22
21	Prevalence of diastolic dysfunction as a possible cause of dyspnea in the elderly. <i>American Journal of Medicine</i> , 2005 , 118, 25-31	2.4	22
20	Echocardiographic indices of left ventricular diastolic dysfunction in 647 individuals with preserved left ventricular systolic function. <i>European Journal of Heart Failure</i> , 2004 , 6, 439-47	12.3	12
19	How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?. <i>Journal of Cardiac Failure</i> , 2004 , 10, 297-303	3.3	95
18	Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. <i>Thrombosis Research</i> , 2004 , 113, 197-204	8.2	31
17	Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. <i>Blood Coagulation and Fibrinolysis</i> , 2003 , 14, 563-7	1	65
16	Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets. <i>Blood Coagulation and Fibrinolysis</i> , 2003 , 14, 249-53	1	33
15	Aggrenox [®] (Extended-Release Dipyridamole and Low-Dose Aspirin in Combination): Protecting Platelets from Excessive Activation in Patients with Vascular Events. <i>Cardiology</i> , 2002 , 2, 93-104		2
14	Effects of in vitro exposure of alcohol on surface receptor expression of human platelets. <i>Clinical Physiology and Functional Imaging</i> , 2002 , 22, 153-6	2.4	10
13	Cell Adhesion Molecules in Cardiovascular Pathology [A Glance into the Future?]. <i>Cardiology</i> , 2001 , 1, 225-235		2
12	Selective Serotonin Reuptake Inhibitors: Future Treatment of Vascular Disease?. <i>Cardiology</i> , 2001 , 1, 332-340		2

11	Platelets and Thrombolysis: Cooperation or Contrariety?. <i>Cardiology</i> , 2001 , 1, 281-290		4
10	Biomarkers and Exercise Training: A Possible Missing Link between Physical Activity and Mortality Benefit in Patients with Heart Failure. <i>Cardiology</i> , 2001 , 1, 110-124		
9	Effect of coronary thrombolysis on the plasma concentration of osteonectin (SPARC, BM40) in patients with acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2000 , 10, 197-202	5.1	5
8	Lack of nuclear apoptosis in cardiomyocytes and increased endothelin-1 levels in a rat heart model of myocardial stunning. <i>Basic Research in Cardiology</i> , 2000 , 95, 308-15	11.8	14
7	Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. <i>Circulation</i> , 2000 , 102, 1221-6	16.7	248
6	Atrioventricular plane motion during dobutamine-atropine stress echocardiography: the biphasic response in healthy subjects revisited. <i>Journal of the American Society of Echocardiography</i> , 2000 , 13, 885-90	5.8	5
5	Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. <i>European Journal of Heart Failure</i> , 1999 , 1, 243-9	12.3	34
4	Excitation-transcription coupling mediated by zinc influx through voltage-dependent calcium channels. <i>Journal of Biological Chemistry</i> , 1995 , 270, 2473-7	5.4	186
3	Relationship between intracellular calcium and contractile force in stunned myocardium. Direct evidence for decreased myofilament Ca ²⁺ responsiveness and altered diastolic function in intact ventricular muscle. <i>Circulation Research</i> , 1995 , 76, 1036-48	15.7	144
2	Magnesium deficiency prolongs myocardial stunning in an open-chest swine model. <i>International Journal of Cardiology</i> , 1994 , 47, 105-15	3.2	17
1	Effects of magnesium supplementation in a porcine model of myocardial ischemia and reperfusion. <i>Journal of Cardiovascular Pharmacology</i> , 1994 , 24, 603-11	3.1	26